Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Новое поколение блокаторов рецепторов ангиотензина
Новое поколение блокаторов рецепторов ангиотензина
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Блокаторы рецепторов ангиотензина (БРА) являются одним из основных классов лекарственных препаратов, применяемых в кардиологии. БРА II поколения – это бифункциональные лекарственные препараты, которые не только блокируют рецепторы ангиотензина 1-го типа, но и оказывают влияние на патогенетические механизмы нарушения обмена углеводов и липидов. Родоначальник II поколения БРА – телмисартан, первый и пока единственный из сартанов II поколения, разрешенный в настоящее время для лечения больных с сердечно-сосудистыми заболеваниями. Лечение телмисартаном пациентов с артериальной гипертензией позволяет эффективно контролировать артериальное давление с достижением его целевого уровня, обеспечивает органопротекцию на разных этапах сердечно-сосудистого континуума, снижает риск развития сердечно-сосудистых заболеваний и смерти от них. Наличие дополнительных свойств и плейотропной активности препарата определяет широкий спектр его применения в кардиологии.
Ключевые слова: телмисартан, блокаторы рецепторов ангиотензина нового поколения, PPAR-γ-рецепторы.
Key words: telmisartan, new-generation angiotensin receptor blockers, PPARγ receptors.
Ключевые слова: телмисартан, блокаторы рецепторов ангиотензина нового поколения, PPAR-γ-рецепторы.
________________________________________________
Key words: telmisartan, new-generation angiotensin receptor blockers, PPARγ receptors.
Полный текст
Список литературы
1. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121 (4 Pt 1): 1244–63.
2. Victor J Dzau, Elliott M Antman, Henry R Black et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114 (25): 2850–70.
3. ESH–ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105–87.
4. Диагностика и лечение артериальной гипертензии. Российские рекомендации (4-й пересмотр). Системные гипертензии. 2010; 3: 3–25.
5. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637–45.
6. Мунгер М.А. Терапия блокаторами рецепторов ангиотензина и кардиоваскулярная протекция. Современная доказательная база и перспективы развития. Кардиоваск. терапия и профилактика. 2011; 10 (7): 93–104.
7. Чазова И.Е., Ратова Л.Г. Первое поколение сартанов: есть ли перспективы? Системные гипертензии. 2010; 4: 5–9.
8. Yusuf S, Teo K, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.
9. Maillard M, Wurzner G, Nussberger J et al. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 2002; 71: 68–76.
10. Elliott W, Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
11. Gress T, Nieto F, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905–12.
12. Kjeldsen S, Naditch-Brule L, Perlini S et al. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardio-metabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008; 26: 2064–70.
13. Shargorodsky M, Hass E, Boaz M et al. High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering. Atherosclerosis 2008; 197: 303–10.
14. Tham DM, Yi-Xin Wang, Rutledge JC. Modulation of Vascular Inflammation by PPARs. Drug News Perspect 2003; 16 (2): 109.
15. The TRANSCEND investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372: 1174–83.
16. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637–45.
17. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002; 16 (Suppl. 2): S13–6.
18. Kakuta H et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25: 41–6.
19. Wienen W et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110: 245–52.
20. Benndorf R, Appel D, Maas R et al. Telmisartan improves endothelial function in patient with essential hypertention. J Cardiovasc Farmacol 2007; 50: 367–71.
21. Tomiyama H, Yamatada J, Koji Y et al. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dymetil-arginine levels. Am J Hypertens 2007; 20: 1305–11.
22. Takai S, Kirimura K et al. Significance of angiotensin II receptor blocker lipophillicities and there protective effects against vascular remodeling. Hipertens Res 2005; 28: 593–600.
23. Williams B, Gosse P, Lowe L. PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006; 24: 193–200.
24. Lacourcire Y, Neutel JM, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19: 104–12.
25. Gosse P, Neutel JM, Schumacher H et al. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit 2007; 12: 141–7.
26. Williams B, Lacourcire Y, Schumacher H et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens 2009; 23 (9): 610–9.
27. Sharma AM, Davidson JA, Gavin JR III, De Sousa NJ. Comparison of the antihypertensive efficacy of telmisartan/hydrochlorothiazide vs valsartan/hydrochlorothiazide in high-risk overweight/obese patients with hypertension and type 2 diabetes. Hypertension 2005; 46: 898–9.
28. Ragot S, Ezzaher A, Meunier A et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens 2002; 16 (12): 865–73.
29. Lacourciere I. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Telmisartan Cough Study Group. Int J Clin Pract 1999; 53: 99–103.
30. The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.
31. Song JC, White CM. Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary 2001; 36: 487–99.
32. Makino H, Haneda M, Babazono T et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy – rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin ii receptor blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) Study. J Int Med Res 2005; 33: 677–86.
33. Barnett AH, Bain SC, Bouter P et al. Diabetics exposed to telmisartan and enalapril study group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351 (19): 1952–61.
34. Galle J, Schwedhelm E, Pinnetti S et al. VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23 (10): 3174–83.
35. Bichu P, Nistala R, Khan A et al. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag 2009; 5: 129–40.
36. Schmieder RE, Delles C, Mimran A et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30 (6): 1351–6.
37. Sharma AM, Hollander A, Koster J; on behalf of the Efficacy and Safety in Patients with Renal Impairment treated with Telmisartan (ESPRIT) Study Group. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 2005; 63 (4): 250–7.
38. Ратова Л.Г., Чазова И.Е. Влияние антигипертензивной терапии микардисом плюс на функцию почек (клинический пример). Системные гипертензии. 2010; 2: 66–70.
2. Victor J Dzau, Elliott M Antman, Henry R Black et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114 (25): 2850–70.
3. ESH–ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105–87.
4. Диагностика и лечение артериальной гипертензии. Российские рекомендации (4-й пересмотр). Системные гипертензии. 2010; 3: 3–25.
5. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637–45.
6. Мунгер М.А. Терапия блокаторами рецепторов ангиотензина и кардиоваскулярная протекция. Современная доказательная база и перспективы развития. Кардиоваск. терапия и профилактика. 2011; 10 (7): 93–104.
7. Чазова И.Е., Ратова Л.Г. Первое поколение сартанов: есть ли перспективы? Системные гипертензии. 2010; 4: 5–9.
8. Yusuf S, Teo K, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.
9. Maillard M, Wurzner G, Nussberger J et al. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 2002; 71: 68–76.
10. Elliott W, Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
11. Gress T, Nieto F, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905–12.
12. Kjeldsen S, Naditch-Brule L, Perlini S et al. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardio-metabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008; 26: 2064–70.
13. Shargorodsky M, Hass E, Boaz M et al. High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering. Atherosclerosis 2008; 197: 303–10.
14. Tham DM, Yi-Xin Wang, Rutledge JC. Modulation of Vascular Inflammation by PPARs. Drug News Perspect 2003; 16 (2): 109.
15. The TRANSCEND investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372: 1174–83.
16. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637–45.
17. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002; 16 (Suppl. 2): S13–6.
18. Kakuta H et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25: 41–6.
19. Wienen W et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110: 245–52.
20. Benndorf R, Appel D, Maas R et al. Telmisartan improves endothelial function in patient with essential hypertention. J Cardiovasc Farmacol 2007; 50: 367–71.
21. Tomiyama H, Yamatada J, Koji Y et al. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dymetil-arginine levels. Am J Hypertens 2007; 20: 1305–11.
22. Takai S, Kirimura K et al. Significance of angiotensin II receptor blocker lipophillicities and there protective effects against vascular remodeling. Hipertens Res 2005; 28: 593–600.
23. Williams B, Gosse P, Lowe L. PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006; 24: 193–200.
24. Lacourcire Y, Neutel JM, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19: 104–12.
25. Gosse P, Neutel JM, Schumacher H et al. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit 2007; 12: 141–7.
26. Williams B, Lacourcire Y, Schumacher H et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens 2009; 23 (9): 610–9.
27. Sharma AM, Davidson JA, Gavin JR III, De Sousa NJ. Comparison of the antihypertensive efficacy of telmisartan/hydrochlorothiazide vs valsartan/hydrochlorothiazide in high-risk overweight/obese patients with hypertension and type 2 diabetes. Hypertension 2005; 46: 898–9.
28. Ragot S, Ezzaher A, Meunier A et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens 2002; 16 (12): 865–73.
29. Lacourciere I. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Telmisartan Cough Study Group. Int J Clin Pract 1999; 53: 99–103.
30. The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.
31. Song JC, White CM. Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary 2001; 36: 487–99.
32. Makino H, Haneda M, Babazono T et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy – rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin ii receptor blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) Study. J Int Med Res 2005; 33: 677–86.
33. Barnett AH, Bain SC, Bouter P et al. Diabetics exposed to telmisartan and enalapril study group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351 (19): 1952–61.
34. Galle J, Schwedhelm E, Pinnetti S et al. VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23 (10): 3174–83.
35. Bichu P, Nistala R, Khan A et al. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag 2009; 5: 129–40.
36. Schmieder RE, Delles C, Mimran A et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30 (6): 1351–6.
37. Sharma AM, Hollander A, Koster J; on behalf of the Efficacy and Safety in Patients with Renal Impairment treated with Telmisartan (ESPRIT) Study Group. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 2005; 63 (4): 250–7.
38. Ратова Л.Г., Чазова И.Е. Влияние антигипертензивной терапии микардисом плюс на функцию почек (клинический пример). Системные гипертензии. 2010; 2: 66–70.
Авторы
В.И.Подзолков, А.И.Тарзиманова*
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
*tarzimanova@mail.ru
*tarzimanova@mail.ru
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
*tarzimanova@mail.ru
________________________________________________
*tarzimanova@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.